|Publication number||US4315002 A|
|Application number||US 06/154,896|
|Publication date||Feb 9, 1982|
|Filing date||May 30, 1980|
|Priority date||Jun 21, 1979|
|Also published as||DE2925009A1, EP0021009A2, EP0021009A3, EP0021009B1|
|Publication number||06154896, 154896, US 4315002 A, US 4315002A, US-A-4315002, US4315002 A, US4315002A|
|Original Assignee||Basf Aktiengesellschaft|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (2), Non-Patent Citations (5), Referenced by (19), Classifications (28), Legal Events (1)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present invention relates to a formulation of certain substances, a process for its preparation, and its use.
Substances such as pharmaceutically active compounds and sensitive materials such as enzymes, which are used as diagnostic agents, must as a rule be converted to an easily usable form. Many possible ways are known, such as tableting, production of dragees, introduction into hard gelatin capsules, etc. However, these processes as a rule consist of a plurality of stages and in many cases are unsuitable for highly sensitive substances.
It is an object of the present invention to provide a formulation of certain substances, which consists of a colyophilizate of the substance and dextran.
Another object is to provide a process for the preparation of the said formulation, wherein an aqueous solution which contains the substance and dextran is introduced into a mold and lyophilized.
A further object is to use the said formulation as a diagnostic agent in combating diseases, and to diagnostic agents or drugs which contain such formulations.
These objects are achieved by the present invention.
The formulation according to the invention does not have the conventional loose form of a lyophilizate which immediately disintegrates under pressure; rather it is, completely surprisingly, in a firm and abrasion-resistant form. The novel process therefore makes it possible even to convert highly sensitive substances, such as enzymes and proteins, into a stable solid form, which has hitherto only been possible in exceptional cases. Furthermore, this form is very abrasion-resistant.
If the formulations are not dried excessively during lyophilization, they can be compression-molded very readily without disintegrating in the process. A further advantage is that only one auxiliary, namely dextran, is necessary for the molding process.
Advantageously, the solution to be lyophilized is filled into molds having the desired shape, for example cylinders or cubes. After lyophilization, the mixture of the substance and dextran is obtained in the form of an abrasion-resistant tablet which can, if desired, be additionally compressed, whereby the rate of solution of the tablet is reduced.
The amount of the substances contained in the novel formulation can be controlled very accurately, which is particularly of importance in the case of diagnostic agents. A special advantage in this context is that even sensitive substances suffer virtually no inactivation during molding. A further advantage is that the formulation very rapidly disintegrates in water or very rapidly dissolves in water, unless it has been compressed.
Sensitive substances are substantially more stable in the novel form than in the pure state and can therefore also be stored for a prolonged period at room temperature, without loss of activity.
Examples of suitable dextrans for the novel formulation are those having molecular weights of 20,000, 40,000 and 60,000. The amount of dextran in the solution to be lyophilized should be not less than about 6%.
All substances which can be dissolved or suspended in water may be incorporated into the formulation. The formulation is particularly suitable for sensitive pharmaceutically active compounds and enzymes for diagnostic purposes and for biochemical analyses. Examples of these are antibiotics, e.g. penicillins, streptomycins and tetracyclins, and enzymes, e.g. fibrinogenase, aminoacid-oxidase, streptokinase, urokinase and caseinase. These substances may be present in the lyophilized product in an amount of from 10 to 50%.
Finally, auxiliaries, e.g. buffers, solubilizing agents or salts, may also be incorporated into the formulation, and this substantially simplifies enzymatic determinations.
The formulations absorb up to about 10% of atmospheric moisture without undergoing a change in their properties. Hence, if moisture-sensitive substances are to be kept as such formulations, the latter must be stored in the absence of atmospheric moisture.
2% of Verapamil are dissolved in a 10% strength solution of a dextran of molecular weight 40,000. 0.5 ml portions of the solution are lyophilized to give moldings which contain 50 mg of dextran and 10 mg of Verapamil. When left exposed to air, the moldings absorb about 6 mg of water.
0.2 ml portions of a mixture of 10 ml of Ancrod solution (containing 70 I.U. of fibrinogenase per ml), 50 ml of a 10% strength solution of a dextran of molecular weight 40,000, which also contains 0.9% of NaCl, and 40 ml of 0.9% strength NaCl solution are lyophilized to form moldings. These each contain 1.2 I.U. of the enzyme and, when dry, weigh 12 mg.
Similar moldings are obtained if solutions of dextran of molecular weight 20,000 or 60,000 are used.
10 ml of Ancrod solution (containing 70 I.U. of fibrinogenase per ml), 50 ml of a 10% strength solution of a dextran of molecular weight 40,000, which also contains 0.9% of NaCl, and 40 ml of buffer are mixed. 0.2 ml portions of the solution are lyophilized to give moldings.
The buffer consisted of 250 ml of an aqueous solution containing 1.838 g of sodium acetate and 7.36 g of sodium barbital, 200 ml of 4.25% strength NaCl solution, 217 ml of 0.1 N HCl and 638 ml of distilled water. The pH of the buffer had been adjusted to 7.4.
To carry out the lyophilization in Examples 1-3, the solutions were pipetted into the hollows of microtitration plates. The solutions were then frozen, and dried at -30° C. and 0.07 mbar.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3655838 *||Mar 20, 1969||Apr 11, 1972||Organon||Method of pelletizing analytical or immunological reagents|
|US4134943 *||Dec 3, 1976||Jan 16, 1979||Boehringer Mannheim Gmbh||Production of porous tablets|
|1||*||Briggs et al.-Chem. Abst., vol. 76 (1972), p. 131,492d.|
|2||*||Kengo-Chem. Abst., vol. 87 (1977), p. 65,650r.|
|3||*||Murakami et al.-Chem. Abst., vol. 83, (1975), p. 136,908y.|
|4||*||Okazaki et al.-Chem. Abst., vol. 86, (1977), p. 127,281y.|
|5||*||Okazaki et al.-Chem. Abst., vol. 87, (1977), p. 106,748m.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4642286 *||May 7, 1984||Feb 10, 1987||Moldowan Mervin J||Composition and method for ethanol determination|
|US4767874 *||Sep 10, 1986||Aug 30, 1988||Shionogi & Co., Ltd.||Stable freeze-dried preparations of an anticancer platinum complex|
|US4793336 *||Dec 5, 1986||Dec 27, 1988||Wang Paul Y||Wound coverings and processes for their preparation|
|US4954522 *||Nov 22, 1988||Sep 4, 1990||Nippon Kayaku Kabushiki Kaisha||Lyophilized preparation of platinum compound|
|US5561121 *||Aug 2, 1994||Oct 1, 1996||American Cyanamid Company||Stable lyophilized thiotepa composition|
|US5605938 *||May 31, 1991||Feb 25, 1997||Gliatech, Inc.||Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate|
|US5705177 *||May 29, 1992||Jan 6, 1998||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US5705178 *||Dec 8, 1993||Jan 6, 1998||Gliatech, Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US5994325 *||Jun 6, 1995||Nov 30, 1999||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6020326 *||Jun 6, 1995||Feb 1, 2000||Gliatech Inc.||Method for inhibition of bone growth by anionic polymers|
|US6083930 *||Jun 6, 1995||Jul 4, 2000||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6127348 *||Sep 1, 1999||Oct 3, 2000||Gliatech, Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6547812||Dec 29, 2000||Apr 15, 2003||Advanced Cardiovascular Systems, Inc.||Radiation therapy using a radioactive implantable device and a radiosensitizer agent|
|US6821959||May 16, 2000||Nov 23, 2004||Istituto Biochimico Pavese Pharma S.P.A||Antibiotic-natural polysaccharide polymer adducts|
|US20040043980 *||Oct 11, 2001||Mar 4, 2004||Pfaendler Hans Rudolf||Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers|
|WO1985005127A1 *||Apr 29, 1985||Nov 21, 1985||Moldowan M||Composition and method for ethanol determination|
|WO1992021354A1 *||May 29, 1992||Dec 10, 1992||Gliatech, Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|WO2000078287A1 *||May 16, 2000||Dec 28, 2000||Istituto Biochimico Pavese Pharma S.P.A.||Antibiotic-natural polysaccharide polymer adducts|
|WO2002040057A1 *||Nov 16, 2001||May 23, 2002||Pharma Biotech Limited||Antibiotics adducts with natural polysaccharide polymers in the form of aqueous solutions|
|U.S. Classification||514/37, 514/59, 514/1, 435/215, 435/219, 514/197, 435/188, 424/94.64, 514/152, 514/619, 435/183, 514/960, 424/94.4, 424/94.63, 435/191, 435/216, 435/217|
|International Classification||G01N33/50, A61K9/19, A61K47/36, A61K49/00|
|Cooperative Classification||Y10S514/96, A61K9/19, G01N33/50, A61K47/36|
|European Classification||G01N33/50, A61K9/19, A61K47/36|
|Sep 8, 1981||AS||Assignment|
Owner name: BASF AKTIENGESELLSCHAFT, 6700 LUDWIGSHAFEN, RHEINL
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:MAURER, ROBERT;REEL/FRAME:003905/0214
Effective date: 19800507